Although, further studies are required to explore CIP2A activity in COPD patients to validate findings by Nath et al. and extrapolate the potential of CIP2A-PP2A activity in the progression to LC, possibly through clinical longitudinal studies. This evidence concerns the gene PTPA and laryngotracheoesophageal cleft.